Immunomedics (IMMU) has been for sale for quite some time, but there hasn't been any interest in it. One reason may be that pharma and biotech companies may be waiting to see the results of a proxy battle to oust the company's founder as well as the CEO, who happens to be his wife.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.